Bristol-Myers Squibb Australia

Company snapshot

Bristol-Myers Squibb Australia maintains 93 tracked programs across Advanced Solid Tumors, Agitation Associated with Alzheimer’s Disease, BP-I mania or mania with mixed features, Mild to moderate Alzheimer’s Disease, Active Psoriatic Arthritis, Schizophrenia, Advanced Malignant Tumors, Moderate to Severe Plaque Psoriasis, Symptomatic Obstructive Hypertrophic Cardiomyopathy, Untreated Unresectable

• 22 approved product(s) across US/EU regulatory metadata.
• 93 active pipeline program(s) linked via ClinicalTrials.gov.
• 93 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Bristol-Myers Squibb Australia. Not investment advice.

• Peer + 0 momentum

  Sunshine Guojian Pharmaceutical

  TA overlap score 40

• Peer + 0 momentum

  Janssen-Cilag International N.V

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for Bristol-Myers Squibb Australia.

1. Jun 8, 2026 Clinical update

   IM101-863 — Phase 3

2. Jun 8, 2026 Clinical update

   IM011-075 — Phase 3

3. Jun 8, 2026 Clinical update

   IM011-054 — Phase 3

4. Jun 8, 2026 Clinical update

   CA224-047 — Phase 3

5. Jun 8, 2026 Clinical update

   CA209-577 — Phase 3

View all clinical trial activity →

• What is Bristol-Myers Squibb Australia?

  Bristol-Myers Squibb Australia is a pharma organization headquartered in Melbourne, AU. Primary therapeutic focus areas include Advanced Solid Tumors, Agitation Associated with Alzheimer’s Disease, BP-I mania or mania with mixed features, Mild to moderate Alzheimer’s Disease, Act

• Is Bristol-Myers Squibb Australia publicly traded?

  Bristol-Myers Squibb Australia appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Bristol-Myers Squibb Australia develop or market?

  We link 120 drug profile(s) where Bristol-Myers Squibb Australia is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/bristol-myers-squibb-pfizer-eeig#company-drugs.

• What are the latest developments for Bristol-Myers Squibb Australia?

  In the last 12 months our linked public records show 93 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Bristol-Myers Squibb Australia focus on?

  Bristol-Myers Squibb Australia focuses on Advanced Solid Tumors, Agitation Associated with Alzheimer’s Disease, BP-I mania or mania with mixed features based on our analysis of their pipeline programs and drug development activities.